Send to

Choose Destination
See comment in PubMed Commons below
Trends Pharmacol Sci. 1993 Sep;14(9):325-31.

Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines.

Author information

  • 1Neuronal Excitability Section, National Institute of Neurological Disorders and Stroke, Bethesda, MD 20892.


NMDA and non-NMDA (AMPA/kainate) antagonists have potential in the treatment of a diverse group of neurological disorders associated with excessive activation of excitatory amino acid receptors. Here Michael Rogawski reviews recent progress in the development of therapeutically useful NMDA receptor channel blockers and a new class of selective AMPA/kainate receptor antagonists, the 2,3-benzodiazepines. Research on these novel noncompetitive excitatory amino acid antagonists has opened promising new avenues for the development of drugs to treat epilepsy, ischaemia, neurodegeneration and Parkinson's disease.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center